Selegiline (deprenyl) treatment and death
of nigral neurons in Parkinson's disease.
Rinne JO, Roytta M, Paljarvi L, Rummukainen J, Rinne UK.
Department of Neurology, University of Turku, Finland
Neurology 1991 Jun;41(6):859-61
We studied the effect of selegiline (deprenyl) treatment on the number of
Lewy bodies and neuron counts in the substantia nigra in patients with
Parkinson's disease (PD). The number of medial nigral neurons was greater
and the number of Lewy bodies fewer in those PD patients who had been
treated with selegiline in combination with levodopa as compared with
patients who had received levodopa alone. This suggests that selegiline
treatment may retard the death of nigral neurons, but alternative
explanations, such as the reduction of levodopa dosage in selegiline-treated
patients, are possible.